var data={"title":"Ethacrynic acid: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ethacrynic acid: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6148?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ethacrynic-acid-drug-information\" class=\"drug drug_general\">see &quot;Ethacrynic acid: Drug information&quot;</a> and <a href=\"topic.htm?path=ethacrynic-acid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ethacrynic acid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167963\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Edecrin;</li>\n      <li>Sodium Edecrin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167964\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Edecrin;</li>\n      <li>Sodium Edecrin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058511\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihypertensive Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diuretic, Loop</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058505\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ethacrynic-acid-drug-information\" class=\"drug drug_general\">see &quot;Ethacrynic acid: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose equivalency for adult patients with normal renal function (approximate): Bumetanide 1 mg = furosemide 40 mg = torsemide 20 mg = ethacrynic acid 50 mg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 1 mg/kg/dose once daily, increase at intervals of 2-3 days to a maximum of 3 mg/kg/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: 1 mg/kg/dose; repeat doses are not routinely recommended, however if indicated, repeat doses every 8-12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 25-400 mg/day in 1-2 divided doses </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: 0.5-1 mg/kg/dose (maximum dose: 100 mg/dose); repeat doses not routinely recommended, however if indicated, repeat every 8-12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167939\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as ethacrynate sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sodium Edecrin: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Edecrin: 25 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167924\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058514\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with food or milk </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: IV: May be infused without further dilution over a period of several minutes or infused slowly through the tubing of a running infusion; should not to be administered IM or SubQ due to local pain and irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25211318\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Discard unused reconstituted solution after 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058513\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Management of edema secondary to CHF, hepatic or renal disease; hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168004\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Edecrin may be confused with Eulexin, Ecotrin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Diuretics are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F168001\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Thrombophlebitis (with intravenous use)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Apprehension, brain disease (patients with preexisting liver disease), chills, confusion, fatigue, headache, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: IgA vasculitis (in patient with rheumatic heart disease), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Abnormal phosphorus levels (variations), abnormal serum calcium (variations), gout, hyperglycemia, hyperuricemia (reversible), hypoglycemia (occurred in two uremic patients who received doses above those recommended), hyponatremia, variations in bicarbonate, variations in CO2 content</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain, anorexia, diarrhea, dysphagia, gastrointestinal hemorrhage, malaise, nausea, vomiting, acute pancreatitis (rare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, severe neutropenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation, local pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Deafness (temporary or permanent), tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167947\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ethacrynic acid or any component of the formulation; anuria; history of severe watery diarrhea caused by this product; infants</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167928\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid/electrolyte loss: Loop diuretics are potent diuretics; excess amounts can lead to profound diuresis with fluid and electrolyte loss; close medical supervision and dose evaluation are required. Watch for and correct electrolyte disturbances; adjust dose to avoid dehydration. In contrast to thiazide diuretics, a loop diuretic can also lower serum calcium concentrations. Electrolyte disturbances can predispose a patient to serious cardiac arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Can rarely occur, however, ethacrynic acid has no cross-reactivity to sulfonamides or sulfonylureas.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Monitor fluid status and renal function in an attempt to prevent oliguria, azotemia, and reversible increases in BUN and creatinine; close medical supervision of aggressive diuresis required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ototoxicity: Rapid IV administration, renal impairment, excessive doses, and concurrent use of other ototoxins is associated with ototoxicity; has been associated with a higher incidence of ototoxicity than other loop diuretics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cirrhosis: In cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antihypertensives: Coadministration of antihypertensives may increase the risk of hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: If given the morning of surgery, ethacrynic acid may render the patient volume depleted and blood pressure may be labile during general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings and precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diuretic resistance: For some patients, despite higher doses of loop diuretic treatment, an adequate diuretic response cannot be attained. Diuretic resistance can usually be overcome by intravenous administration, the use of two diuretics together (eg, furosemide and chlorothiazide), or the use of a diuretic with a positive inotropic agent. When such combinations are used, serum electrolytes need to be monitored even more closely (Cody 1994; ACC/AHA [Yancy 2013]; HFSA 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299289\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167933\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12901&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Loop Diuretics may enhance the adverse/toxic effect of Allopurinol. Loop Diuretics may increase the serum concentration of Allopurinol. Specifically, Loop Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Loop Diuretics may enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Loop Diuretics may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: Loop Diuretics may enhance the QTc-prolonging effect of Bilastine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Loop Diuretics.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: May enhance the hypotensive effect of Loop Diuretics. Management: If canagliflozin is combined with a loop diuretic, monitor for symptoms of intravascular volume depletion and hypotension. Canadian product labeling recommends avoiding the combination of canagliflozin and loop diuretics.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Loop Diuretics may enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefotiam: Loop Diuretics may enhance the nephrotoxic effect of Cefotiam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpirome: Loop Diuretics may enhance the nephrotoxic effect of Cefpirome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceftizoxime: Loop Diuretics may enhance the nephrotoxic effect of Ceftizoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Loop Diuretics may enhance the nephrotoxic effect of Cephalothin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: Loop Diuretics may enhance the nephrotoxic effect of CISplatin. Loop Diuretics may enhance the ototoxic effect of CISplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Loop Diuretics may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: Loop Diuretics may enhance the QTc-prolonging effect of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Empagliflozin: May enhance the hypotensive effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: Loop Diuretics may increase the serum concentration of Foscarnet. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May diminish the diuretic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Furosemide: May enhance the ototoxic effect of Ethacrynic Acid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipragliflozin: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk for intravascular volume depletion may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Loop Diuretics may enhance the arrhythmogenic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Loop Diuretics may enhance the adverse/toxic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Licorice: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Loop Diuretics may decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate may increase the serum concentration of Loop Diuretics. Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Loop Diuretics may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May diminish the diuretic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics. Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: Loop Diuretics may enhance the QTc-prolonging effect of Promazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: May enhance the hypokalemic effect of Loop Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RisperiDONE: Loop Diuretics may enhance the adverse/toxic effect of RisperiDONE.  Management: Consider alternative diuretic therapy (e.g., thiazides) to more potent diuretics (e.g., furosemide) in elderly patients receiving risperidone. Patients who require use of more potent diuretic therapy should be closely monitored and adequately hydrated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tobramycin (Oral Inhalation): Loop Diuretics may enhance the nephrotoxic effect of Tobramycin (Oral Inhalation). Loop Diuretics may enhance the ototoxic effect of Tobramycin (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Loop Diuretics may enhance the hypokalemic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Ethacrynic Acid may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk of hypovolemia, electrolyte disturbances, and prerenal azotemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167934\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167950\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058510\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes, blood pressure, renal function, hearing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167927\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits reabsorption of sodium and chloride in the ascending loop of Henle and distal renal tubule, interfering with the chloride-binding cotransport system, thus causing increased excretion of water, sodium, chloride, magnesium, and calcium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167946\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Diuresis: Oral: ~30 minutes; IV: 5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Oral: 2 hours; IV: 30 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Oral: 12 hours; IV: 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (35% to 40%) to active cysteine conjugate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Normal renal function: 2-4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces and urine (30% to 60% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167945\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL oral suspension may be made with ethacrynic acid powder. Dissolve 120 mg ethacrynic acid powder in a small amount of 10% alcohol. Add a small amount of 50% sorbitol solution and stir. Adjust pH to 7 with 0.1N sodium hydroxide solution. Add sufficient quantity of 50% sorbitol solution to make a final volume of 120 mL. Add methylparaben 6 mg and propylparaben 2.4 mg as preservatives. Stable for 220 days at room temperature.</p>\n    <div class=\"reference\">Das Gupta V, Gibbs CW Jr, and Ghanekar AG, &quot;Stability of Pediatric Liquid Dosage Forms of Ethacrynic Acid, Indomethacin, Methyldopate Hydrochloride, Prednisone and Spironolactone,&quot; <i>Am J Hosp Pharm</i>, 1978, 35(11):1382-5.<span class=\"pubmed-id\">568384</span></div>\r\n\n    <div class=\"reference\">\n      <i>Handbook on Extemporaneous Formulations</i>, Bethesda, MD: American Society of Hospital Pharmacists, 1987.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167949\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ethacrynate Sodium Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $4,560.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Sodium Edecrin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $6,017.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Edecrin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $2,933.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ethacrynic Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $2,394.99</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038612\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Edecril (NL);</li>\n      <li>Edecrin (AT, AU, BB, CZ, GB, IE, NL);</li>\n      <li>Edecrina (SE);</li>\n      <li>Hydromedin (DE);</li>\n      <li>Hydromedin i.v.[inj.] (DE);</li>\n      <li>Reomax (IT);</li>\n      <li>Uregyt (CZ, DE, HN, HU, RU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cody RJ, Kubo SH, and Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. <i>Arch Intern Med.</i> 1994;154(17):1905-1914. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/8074594/pubmed\" target=\"_blank\" id=\"8074594\">8074594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sparrow AW, Friedberg DZ, Nadas AS. The use of ethacrynic acid in infants and children with congestive heart failure. <i>Pediatrics</i>. 1968;42(2):291-302.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/5663735 /pubmed\" target=\"_blank\" id=\"5663735 \">5663735 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ethacrynic-acid-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12901 Version 148.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F167963\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F167964\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058511\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058505\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F167939\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F167924\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058514\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25211318\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058513\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F168004\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F168001\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F167947\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F167928\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299289\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F167933\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F167934\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F167950\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058510\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F167927\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F167946\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F167945\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F167949\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038612\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12901|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ethacrynic-acid-drug-information\" class=\"drug drug_general\">Ethacrynic acid: Drug information</a></li><li><a href=\"topic.htm?path=ethacrynic-acid-patient-drug-information\" class=\"drug drug_patient\">Ethacrynic acid: Patient drug information</a></li></ul></div></div>","javascript":null}